Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | IDH1 | O75874 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28582091 | 0.81 | RBP4 (0.34) | MEN1KMT2ACRHBPCRHR2BRD4 | |
| SCHEMBL28092792 | 0.77 | HSD17B3 (0.38) | EPHX2HSD17B3MEN1KMT2AGAA | |
| SCHEMBL10226402 | 0.75 | GAA (0.41) | EPHX2HSD17B3MEN1KMT2AGAA | |
| SCHEMBL3796963 | 0.74 | NOTUM (0.51) | — | |
| SCHEMBL29220851 | 0.73 | HTT (0.38) | HSD17B3MEN1KMT2AGAABRPF1 | |
| SCHEMBL29220793 | 0.73 | XIAP (0.37) | HSD17B3MEN1KMT2AGAABRPF1 | |
| SCHEMBL28092690 | 0.72 | GAA (0.36) | HSD17B3MEN1KMT2AGAABRPF1 | |
| SCHEMBL29220790 | 0.72 | MEN1 (0.40) | MEN1KMT2AGAASMN1; SMN2BRD4 | |
| SCHEMBL16722422 | 0.71 | NOTUM (0.55) | HSD17B3MEN1KMT2AGAABRPF1 | |
| SCHEMBL16722424 | 0.71 | NOTUM (0.55) | HSD17B3MEN1KMT2AGAABRPF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002464-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SAPIENSBIO INC. (KR) | 2025-01-02 | — | — | US | disclosed |
| EP-4421070-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Sapiensbio Inc. (KR) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023068755-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 사피엔스바이오 | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002464-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | RHOA, ACTR2, MFAP1 | EPHX2 2233/4885HSD17B3 4030/4885MEN1 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.